Page 120 - 《中国药房》2022年7期

or metastatic hepatocellular carcinoma[J]. Clin Cancer Inst，2021，113（10）：1396-1404.
Res，2021，27（7）：1836-1841. [16] SCHOENFELD J D，NISHINO M，SEVERGNINI M，
[ 8 ] NARAYAN P，WAHBY S，GAO J J，et al. FDA approval et al. Pneumonitis resulting from radiation and immune
summary：atezolizumab plus paclitaxel protein-bound for checkpoint blockade illustrates characteristic clinical，
the treatment of patients with advanced or metastatic radiologic and circulating biomarker features[J]. J Immu-
TNBC whose tumors express PD-L1[J]. Clin Cancer Res， nother Cancer，2019，7（1）：112.
2020，26（10）：2284-2289. [17] TENG F F，LI M，YU J M. Radiation recall pneumonitis
[ 9 ] VELLANKI P J，MULKEY F，JAIGIRDAR A A，et al. induced by PD-1/PD-L1 blockades：mechanisms and
FDA approval summary：nivolumab with ipilimumab and therapeutic implications[J]. BMC Med，2020，18（1）：275.
chemotherapy for metastatic non-small cell lung cancer，a [18] COUSIN F，DESIR C，BEN MUSTAPHA S，et al. Inci-
collaborative project orbis review[J]. Clin Cancer Res， dence，risk factors，and CT characteristics of radiation re-
2021，27（13）：3522-3527. call pneumonitis induced by immune checkpoint inhibitor
[10] KENNEDY L B，SALAMA A K S. A review of cancer im- in lung cancer[J]. Radiother Oncol，2021，157：47-55.
munotherapy toxicity[J]. CA Cancer J Clin，2020，70（2）： [19] RAMOS-CASALS M，BRAHMER J R，CALLAHAN M
86-104. K，et al. Immune-related adverse events of checkpoint
[11] ALOMAR M，TAWFIQ A M，HASSAN N，et al. Post mar- inhibitors[J]. Nat Rev Dis Primers，2020，6（1）：38.
keting surveillance of suspected adverse drug reactions [20] IMAGAWA A. Two types of fulminant type 1 diabetes
through spontaneous reporting：current status，challenges mellitus：immune checkpoint inhibitor-related and conven-
and the future[J]. Ther Adv Drug Saf，2020，11： tional[J]. J Diabetes Investig，2021，12（6）：917-919.
2042098620938595. [21] BOSWELL L，CASALS G，BLANCO J，et al. Onset of
[12] SAKAEDA T，TAMON A，KADOYAMA K，et al. Data fulminant type 1 diabetes mellitus following hypophysitis
mining of the public version of the FDA Adverse Event after discontinuation of combined immunotherapy. A case
Reporting System[J]. Int J Med Sci，2013，10（7）：796- report[J]. J Diabetes Investig，2021，12（12）：2263-2266.
803. [22] ALBERTI A，MANCIN M，CORTINOVIS D，et al.
[13] LICHTENSTEIN M R L，NIPP R D，MUZIKANSKY A， Disseminated intravascular coagulation in advanced lung
et al. Impact of age on outcomes with immunotherapy adenocarcinoma during first-line pembrolizumab[J].
in patients with non-small cell lung cancer[J]. J Thorac Immunotherapy，2020，12（9）：629-633.
Oncol，2019，14（3）：547-552. [23] YE X F，HU F Y，ZHAI Y H，et al. Hematological toxici-
[14] SAMANI A，ZHANG S，SPIERS L，et al. Impact of age ties in immune checkpoint inhibitors：a pharmacovigi-
on the toxicity of immune checkpoint inhibition[J]. J Im- lance study from 2014 to 2019[J]. Hematol Oncol，2020，
munother Cancer，2020，8（2）：e000871. 38（4）：565-575.
[15] JING Y，ZHANG Y C，WANG J，et al. Association （收稿日期：2021-09-15 修回日期：2022-03-19）
between sex and immune-related adverse events during （编辑：胡晓霖）
immune checkpoint inhibitor therapy[J]. J Natl Cancer

《中国药房》杂志——中文核心期刊，欢迎投稿、订阅

·878 · China Pharmacy 2022 Vol. 33 No. 7 中国药房 2022年第33卷第7期